<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; best</title>
	<atom:link href="http://www.tapanray.in/tag/best/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Paying For The Best Health Outcomes At The Lowest Possible Cost</title>
		<link>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=paying-for-the-best-health-outcomes-at-the-lowest-possible-cost</link>
		<comments>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/#comments</comments>
		<pubDate>Mon, 08 Dec 2014 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Burrill]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Levitra (vardenafil)]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Michael Porter]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[OBP]]></category>
		<category><![CDATA[Outcomes. Lowest]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[QALY]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas Lee]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>
		<category><![CDATA[Velcade (bortezomib)]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6244</guid>
		<description><![CDATA[“Bayer CEO Dr. Marijn Dekkers is happy to have fair Outcomes-Based Pricing”, reported ‘PharmaTimes’ on December 3, 2014. Dr. Dekkers was quoted saying, “It is okay to be tested on that in the process of price-setting, that is fine, we should &#8230; <a href="http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Contract Research – a rapidly evolving business opportunity in India: Is the Pharmaceutical Industry making the best use of it?</title>
		<link>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it</link>
		<comments>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 01:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rapidly]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=845</guid>
		<description><![CDATA[A quick perspective of the ‘new-era’ pharmaceutical R&#38;D in India: Since 1970 up until 2005, Indian pharmaceutical industry used to be considered as the industry of ‘reverse engineering’ and that too with an underlying disparaging tone&#8230; and also as the &#8230; <a href="http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
